A real-world study has found that chemotherapy plus bevacizumab may improve survival in patients with refractory colorectal cancer. The treatment combination is being explored as a potential option for metastatic colorectal cancer, with some studies examining its use in conjunction with other therapies. The effectiveness of chemotherapy plus bevacizumab, possibly in combination with other treatments like trifluridine-tipiracil, is being investigated as a potential solution for patients with limited treatment options.